These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15902815)

  • 21. [Sirolimus-eluting stents to treat lesions with a high risk of restenosis. Six-month clinical follow-up in the first 100 patients].
    de la Torre Hernández JM; Burgos V; González-Enríquez S; Cobo M; Zueco J; Figueroa A; Colman T
    Rev Esp Cardiol; 2004 Feb; 57(2):116-22. PubMed ID: 14967106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
    Jiménez-Quevedo P; Sabaté M; Angiolillo DJ; Alfonso F; Hernández-Antolín R; SanMartín M; Gómez-Hospital JA; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Eur Heart J; 2007 Aug; 28(16):1946-52. PubMed ID: 17562666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis.
    Saia F; Lemos PA; Hoye A; Sianos G; Arampatzis CA; de Feyter PJ; van der Giessen WJ; Smits PC; van Domburg RT; Serruys PW
    Catheter Cardiovasc Interv; 2004 Jul; 62(3):283-8. PubMed ID: 15224289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
    Moses JW; Nikolsky E; Mehran R; Cambier PA; Bachinsky WB; Leya F; Kuntz RE; Popma JJ; Schleckser P; Wang H; Cohen SA; Leon MB;
    Am J Cardiol; 2006 Dec; 98(11):1455-60. PubMed ID: 17126649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
    Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
    Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late restenosis following sirolimus-eluting stent implantation.
    Cosgrave J; Corbett SJ; Melzi G; Babic R; Biondi-Zoccai GG; Airoldi F; Chieffo A; Sangiorgi GM; Montorfano M; Michev I; Carlino M; Colombo A
    Am J Cardiol; 2007 Jul; 100(1):41-4. PubMed ID: 17599438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study.
    Saia F; Lemos PA; Lee CH; Arampatzis CA; Hoye A; Degertekin M; Tanabe K; Sianos G; Smits PC; McFadden E; Hofma SH; van der Giessen WJ; de Feyter PJ; van Domburg RT; Serruys PW
    Circulation; 2003 Oct; 108(16):1927-9. PubMed ID: 14557354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Two-year clinical follow-up in 200 patients receiving sirolimus-eluting stents in lesions at a high risk of restenosis].
    de la Torre-Hernández JM; Sainz-Laso F; Llano-Cardenal M; Ruiz-Lera M; Fernández-Friera L; Burgos V; Zueco J; Figueroa A; Colman T
    Rev Esp Cardiol; 2006 Mar; 59(3):225-31. PubMed ID: 16712746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of in-stent restenosis with sirolimus-eluting-stents -- a six month clinical and angiographic follow-up.
    Rau M; Maikowski C; Weber M; Keil E; Elsässer A; Möllmann H; Hamm C
    Z Kardiol; 2005 Nov; 94(11):742-7. PubMed ID: 16258776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.
    Morice MC; Serruys PW; Barragan P; Bode C; Van Es GA; Stoll HP; Snead D; Mauri L; Cutlip DE; Sousa E
    J Am Coll Cardiol; 2007 Oct; 50(14):1299-304. PubMed ID: 17903626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease.
    Degertekin M; Regar E; Tanabe K; Lee CH; Serruys PW
    Minerva Cardioangiol; 2002 Oct; 50(5):405-18. PubMed ID: 12384623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent.
    Cosgrave J; Melzi G; Corbett S; Biondi-Zoccai GG; Babic R; Airoldi F; Chieffo A; Sangiorgi GM; Montorfano M; Michev I; Carlino M; Colombo A
    Am Heart J; 2007 Mar; 153(3):354-9. PubMed ID: 17307411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early- and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent failure.
    Lee SS; Price MJ; Wong GB; Valencia R; Damani S; Sawhney N; Gollapudi RR; Schatz RA; Teirstein PS
    Am J Cardiol; 2006 Nov; 98(10):1345-8. PubMed ID: 17134626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sirolimus-eluting stents for the treatment of in-stent restenosis.
    Degertekin M; Saia F; Lemos PA; Arampatzis CA; Serruys PW
    Minerva Cardioangiol; 2003 Oct; 51(5):475-84. PubMed ID: 14551517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.